HSV-2 Recurrence Treatment
For recurrent HSV-2 infections, initiate episodic antiviral therapy (acyclovir 800 mg twice daily, valacyclovir 500 mg twice daily, or famciclovir 125 mg twice daily for 5 days) at the first sign of prodrome or lesions, or use daily suppressive therapy (acyclovir 400 mg twice daily, valacyclovir 500-1000 mg daily, or famciclovir 250 mg twice daily) if experiencing ≥6 recurrences per year. 1
Treatment Approach: Two Strategies
Episodic Therapy for Acute Recurrences
Timing is critical: Treatment must begin during prodrome or within 1 day of lesion onset to achieve benefit 1. Provide patients with medication or a prescription in advance so they can self-initiate treatment immediately when symptoms begin.
Recommended regimens (choose one) 1:
- Acyclovir 800 mg orally twice daily for 5 days (simplest dosing)
- Acyclovir 400 mg orally three times daily for 5 days
- Acyclovir 200 mg orally five times daily for 5 days
- Valacyclovir 500 mg orally twice daily for 5 days
- Famciclovir 125 mg orally twice daily for 5 days
Shorter course option: A 2-day regimen of acyclovir 800 mg three times daily significantly reduces lesion duration (4 vs 6 days), episode duration, and viral shedding compared to placebo, offering a more convenient alternative 2.
Suppressive Therapy for Frequent Recurrences
Indications: Recommend for patients with ≥6 recurrences per year 1. Suppressive therapy reduces recurrence frequency by ≥75% and improves quality of life.
Recommended regimens (choose one) 1:
- Acyclovir 400 mg orally twice daily (longest safety data: 6 years)
- Valacyclovir 500 mg orally once daily (convenient once-daily dosing)
- Valacyclovir 1000 mg orally once daily
- Famciclovir 250 mg orally twice daily
Important caveat: Valacyclovir 500 mg once daily is less effective in patients with very frequent recurrences (≥10 episodes/year); use higher doses or twice-daily regimens for these patients 1.
Key Clinical Considerations
Duration of suppressive therapy: After 1 year of continuous suppression, discuss discontinuation with the patient to reassess recurrence frequency, as many patients experience decreased recurrence rates over time 1. Acyclovir has documented safety for up to 6 years of continuous use 1.
Resistance concerns: Clinically significant acyclovir resistance has not emerged among immunocompetent patients receiving suppressive therapy 1.
Transmission reduction: While suppressive therapy reduces asymptomatic viral shedding, it does not eliminate it completely. The extent to which suppression prevents transmission remains incompletely defined 1.
Severe Disease Management
For patients requiring hospitalization due to disseminated infection, pneumonitis, hepatitis, or CNS complications (meningitis/encephalitis):
Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution 1
Common Pitfalls to Avoid
- Delayed treatment initiation: Episodic therapy only works if started during prodrome or within 24 hours of lesion onset. Patients must have medication readily available.
- Underdosing in frequent recurrers: Don't use valacyclovir 500 mg once daily if patient has ≥10 episodes/year.
- Premature discontinuation: Assess suppressive therapy effectiveness after at least 1 year before stopping.
- Inadequate counseling: Patients need to understand that suppressive therapy reduces but doesn't eliminate transmission risk, and condom use remains important 1.
Patient Education Essentials
Counsel all patients on 1:
- Natural history with potential for recurrent episodes
- Asymptomatic viral shedding occurs and can transmit infection
- Abstain from sexual activity when lesions or prodromal symptoms present
- Condom use during all sexual exposures with new/uninfected partners
- For women of childbearing age: inform prenatal care providers about HSV-2 status